STI Testing Guide: What, When, and Where Topical Map

Within one week you can get baseline testing: NAAT (urine or swab) for chlamydia and gonorrhea and a baseline fourth‑generation HIV test or HIV RNA PCR if high‑risk exposure; many STIs have longer window periods so plan repeat tests at recommended intervals (usually 2–12 weeks depending on the infection). Urgent concerns (possible HIV needle exposure or recent high‑risk sexual exposure) may warrant immediate PEP evaluation and an HIV RNA test.

Window periods vary: NAATs for chlamydia/gonorrhea are usually accurate 1–5 days after exposure if symptoms develop but guidelines recommend testing at 1–2 weeks for symptomatic exposure and repeat at 2–3 months for asymptomatic. HIV fourth‑generation tests typically detect most infections by 18–45 days; RNA PCR can detect infection within 10–12 days; syphilis serology can take 3–6 weeks to turn positive.

High‑quality at‑home kits that use NAAT or lab‑processed blood/serology are comparable to clinic testing when instructions are followed and samples are sent to accredited labs; however, some rapid fingerstick or antigen self‑tests have lower sensitivity, so verify the kit’s lab accreditation and the tests used (NAAT vs lateral flow) before purchasing. For visible symptoms or urgent exposures, in‑person evaluation is recommended.

Many public clinics, Planned Parenthood, and community health centers offer confidential testing; in some regions minors can consent to STI services without parental involvement. If using a parent’s insurance, ask the provider about confidential billing practices and state laws — alternatively use a confidential clinic, pay cash, or order an accredited at‑home test to avoid EOB disclosures.

NAATs are site‑specific: throat swabs for oropharyngeal exposure, anal/rectal swabs for receptive anal sex, and urine or vaginal swabs for urogenital exposure; a single urine test won’t detect pharyngeal or rectal infections. Tell the clinician your sexual practices so they can order multi‑site testing where indicated.

CDC recommends test‑of‑cure only in certain situations (e.g., pregnant people treated for chlamydia), but a repeat test for reinfection is advised approximately 3 months after treatment for both chlamydia and gonorrhea. If symptoms persist after treatment, seek immediate re‑evaluation.

False positives are uncommon with highly specific lab tests (especially NAAT and confirmatory syphilis testing) but can occur with low pretest probability; false negatives are more common during window periods or with improper sample collection. If results conflict with symptoms or exposure history, repeat testing with appropriate timing or alternative modalities (e.g., RNA PCR for early HIV) is recommended.

Notify recent partners promptly with dates of potential exposure and recommend they get tested and treated; many clinics and public health departments offer anonymous partner notification or messaging services and can provide templates and local resources. For bacterial STIs, partners should be treated promptly even if testing is pending; for HIV, linkage to care and immediate contact tracing is critical.

In many countries, diagnoses like chlamydia, gonorrhea, syphilis, and HIV are reportable to public health authorities; reporting facilitates partner notification, outbreak tracking, and access to treatment programs. Reporting typically uses de‑identified clinical data and varies by jurisdiction — include a local resources section that explains state/country reporting rules.

MSM with multiple partners should have at least annual screening for HIV and site‑specific NAATs more frequently (every 3 months if high risk); pregnant people should be screened for HIV, syphilis, chlamydia, and gonorrhea at first prenatal visit and retested in third trimester if high risk. Sexually active adolescents benefit from annual screening for chlamydia/gonorrhea and HPV vaccination counseling; tailor schedules by risk and local guidelines.